Eventide Asset Management - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 1 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
Eventide Asset Management ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q4 2015$6,593,000
+173.3%
420,500
+83.8%
0.33%
+135.7%
Q3 2015$2,412,000
-66.9%
228,800
-20.7%
0.14%
-64.5%
Q2 2015$7,281,000
-9.5%
288,7000.0%0.39%
-34.9%
Q1 2015$8,046,000
+52.7%
288,7000.0%0.60%
+5.2%
Q4 2014$5,269,000
+40.8%
288,7000.0%0.58%
+10.2%
Q3 2014$3,742,000
-20.6%
288,7000.0%0.52%
-18.6%
Q2 2014$4,712,000
-7.6%
288,7000.0%0.64%
-19.1%
Q1 2014$5,101,000
-18.0%
288,700
+12.3%
0.79%
-58.7%
Q4 2013$6,222,000257,0001.92%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q3 2023
NameSharesValueWeighting ↓
KLP Enterprises, LLC 6,865,000$1,359,000100.00%
TSP Capital Management Group, LLC 236,919$1,197,0000.67%
Meditor Group Ltd 6,312,700$1,249,0000.26%
Anson Funds Management LP 1,229,844$243,0000.14%
Cresset Asset Management, LLC 6,865,000$1,359,0000.08%
Telemetry Investments, L.L.C. 348,501$69,0000.04%
GSA CAPITAL PARTNERS LLP 789,260$156,0000.02%
Benchmark Capital Advisors 32,600$6,0000.01%
BOENNING & SCATTERGOOD, INC. 74,950$15,0000.01%
Stratos Wealth Partners, LTD. 250,000$49,0000.00%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders